Federal Containment Level 2 license will support testing and validation for studies and sale of natural products VANCOUVER, BC, March 14, 2022 /CNW/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), a mental healthcare company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that its research lab…


Previous articlePsychedelic Bulletin: Tensions Rise among Oregon’s Psilocybin Advisory Board; Colleges Team up to Develop Psychedelic Curriculum
Next articlePT301 – Kabir Ali – Addiction, Ketamine, and the Overlooked Gift of Self-Love